Literature DB >> 31608423

Applying Pharmacodynamics and Antimicrobial Stewardship to Pediatric Preseptal and Orbital Cellulitis.

Grant T Stimes1,2, Jennifer E Girotto3,4.   

Abstract

Orbital and preseptal cellulitis are most commonly caused by organisms that originate in the upper respiratory tract or from the skin. There is significant variation in antibiotics used, but ampicillin-sulbactam, ceftriaxone, metronidazole, clindamycin, amoxicillin, amoxicillin-clavulanate, cefuroxime, and vancomycin are often used in the treatment of these infections. The choice of antibiotic, however, is only one consideration. It is also important that antibiotics are dosed to optimize their pharmacodynamic target attainment. Like other serious infections, therapy can be transitioned from initial intravenous therapy to an oral regimen when there are clear signs of clinical and laboratory improvement. The total duration of therapy for these infections have also been decreasing in recent years with durations of approximately 2 weeks becoming more common, even for orbital or subperiosteal infections. Antimicrobial stewardship programs can work closely with providers who manage these infections to create pathways, choose optimal antibiotics and dosage, transition from intravenous to oral therapy, and provide shortest effective durations.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31608423     DOI: 10.1007/s40272-019-00357-3

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  48 in total

1.  Endocarditis due to anaerobic gram-negative bacilli.

Authors:  L J Nastro; S M Finegold
Journal:  Am J Med       Date:  1973-04       Impact factor: 4.965

2.  The pathogenesis of orbital complications in acute sinusitis.

Authors:  J R Chandler; D J Langenbrunner; E R Stevens
Journal:  Laryngoscope       Date:  1970-09       Impact factor: 3.325

3.  A ten year retrospective review of orbital complications secondary to acute sinusitis in children.

Authors:  D N Pengiran Suhaili; B S Goh; B S Gendeh
Journal:  Med J Malaysia       Date:  2010-03

4.  Pharmacokinetic and Pharmacodynamic Properties of Metronidazole in Pediatric Patients With Acute Appendicitis: A Prospective Study.

Authors:  Jason Child; Xinhui Chen; Rakesh D Mistry; Stig Somme; Christine MacBrayne; Peter L Anderson; Ronald N Jones; Sarah K Parker
Journal:  J Pediatric Infect Dis Soc       Date:  2019-09-25       Impact factor: 3.164

Review 5.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

6.  Conservative treatment in rhinosinusitis orbital complications in children aged 2 years and younger.

Authors:  Ephraim Eviatar; Haim Gavriel; Koby Pitaro; Michael Vaiman; Michael Goldman; Alex Kessler
Journal:  Rhinology       Date:  2008-12       Impact factor: 3.681

7.  Orbital cellulitis in children-medical treatment versus surgical management.

Authors:  Morgan Yang; Boon Long Quah; Lay Leng Seah; Audrey Looi
Journal:  Orbit       Date:  2009

8.  Pharmacokinetics and bactericidal activity of cefuroxime axetil.

Authors:  C M Ginsburg; G H McCracken; M Petruska; K Olson
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

9.  Preseptal and orbital cellulitis: 15-year experience with sulbactam ampicillin treatment.

Authors:  Ilker Devrim; Güler Kanra; Ateş Kara; A Bülent Cengiz; Mehmet Orhan; Mehmet Ceyhan; Gülten Seçmeer
Journal:  Turk J Pediatr       Date:  2008 May-Jun       Impact factor: 0.552

10.  Orbital cellulitis and brain abscess - rare complications of maxillo-spheno-ethmoidal rhinosinusitis.

Authors:  Farah Constantin; Patricia-Alexandra Niculescu; Oana Petre; Daniel Balasa; Alexandru Tunas; Ioana Rusu; Mihai Lupascu; Cristiana Orodel
Journal:  Rom J Ophthalmol       Date:  2017 Apr-Jun
View more
  1 in total

1.  Distinguishing orbital cellulitis from preseptal cellulitis in children.

Authors:  Rumeysa Yalçınkaya; Gönül Tanır; Meltem Polat; Suna Özdem; Zeynep Savaş Şen; Rüveyda Gümüşer Cinni; Aslıhan Yüce Sezen; Fatma Nur Öz
Journal:  Int Ophthalmol       Date:  2022-09-02       Impact factor: 2.029

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.